Carmen J Allegra

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 31:359-64. 2013
  2. ncbi Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
  3. ncbi National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
    Carmen J Allegra
    University of Florida Shands Cancer Center, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Natl Cancer Inst 102:161-9. 2010
  4. ncbi Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 29:11-6. 2011
  5. ncbi Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
  6. ncbi NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)
    Carmen J Allegra
    University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida, USA
    NIH Consens State Sci Statements 26:1-27. 2009
  7. ncbi American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    Carmen J Allegra
    Division of Hematology Oncology, Department of Medicine, University of Florida Shands CancerCenter, Gainesville, FL, USA
    J Clin Oncol 27:2091-6. 2009

Detail Information

Publications7

  1. ncbi Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 31:359-64. 2013
    ..Our report summarizes the primary and secondary end points of disease-free and overall survival, respectively, with 5 years median follow-up time...
  2. ncbi Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
    ..We present safety information in advance of the planned analysis of efficacy...
  3. ncbi National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
    Carmen J Allegra
    University of Florida Shands Cancer Center, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Natl Cancer Inst 102:161-9. 2010
    ..To provide health-care providers, patients, and the general public with a responsible assessment of currently available data on the diagnosis and management of ductal carcinoma in situ (DCIS)...
  4. ncbi Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 29:11-6. 2011
    ....
  5. ncbi Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
    ..The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma...
  6. ncbi NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)
    Carmen J Allegra
    University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida, USA
    NIH Consens State Sci Statements 26:1-27. 2009
    ..To provide health care providers, patients, and the general public with a responsible assessment of currently available data on the diagnosis and management of ductal carcinoma in situ (DCIS)...
  7. ncbi American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    Carmen J Allegra
    Division of Hematology Oncology, Department of Medicine, University of Florida Shands CancerCenter, Gainesville, FL, USA
    J Clin Oncol 27:2091-6. 2009
    ..ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of ASCO's PCOs, or for any errors or omissions...